ω-3 Fatty acids for major depressive disorder in adults: an abridged Cochrane review.

Appleton, K., Sallis, H.M., Perry, R., Ness, A.R. and Churchill, R., 2016. ω-3 Fatty acids for major depressive disorder in adults: an abridged Cochrane review. BMJ Open, 6 (3), e010172.

Full text available as:

[img]
Preview
PDF
Cochraneabridged.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial.

2MB

DOI: 10.1136/bmjopen-2015-010172

Abstract

OBJECTIVE: To assess the effects of n-3 polyunsaturated fatty acids (n-3PUFAs; also known as ω-3 fatty acids) compared with comparator for major depressive disorder (MDD) in adults. DESIGN: Systematic review and meta-analyses. DATA SOURCES: The Cochrane Depression, Anxiety and Neurosis Review Group's Specialised Registers (CCDANCTR) and International Trial Registries searched to May 2015. CINAHL searched to September 2013. TRIAL SELECTION: INCLUSION CRITERIA: a randomised controlled trial (RCT); that provided n-3PUFAs as an intervention; used a comparator; measured depressive symptomology as an outcome; and was conducted in adults with MDD. OUTCOMES: Primary outcomes were depressive symptomology and adverse events. RESULTS: 20 trials encompassing 26 relevant studies were found. For n-3PUFAs versus placebo, n-3PUFA supplementation resulted in a small-to-modest benefit for depressive symptomology: SMD=-0.32 (95% CI -0.52 to -0.12; 25 studies, 1373 participants, very low-quality evidence), but this effect is unlikely to be clinically meaningful, is very imprecise and, based on funnel plot inspection, sensitivity analyses and comparison with large well-conducted trials, is likely to be biased. Considerable evidence of heterogeneity between studies was also found, and was not explained by subgroup or sensitivity analyses. Numbers of individuals experiencing adverse events were similar in intervention and placebo groups (OR=1.24, 95% CI 0.95 to 1.62; 19 studies, 1207 participants; very low-quality evidence). For n-3PUFAs versus antidepressants, no differences were found between treatments in depressive symptomology (MD=-0.70 (95% CI -5.88 to 4.48); 1 study, 40 participants, very low-quality evidence). CONCLUSIONS: At present, we do not have sufficient evidence to determine the effects of n-3PUFAs as a treatment for MDD. Further research in the form of adequately powered RCTs is needed.

Item Type:Article
ISSN:2044-6055
Uncontrolled Keywords:Epidemiology; Nutrition and dietetics; Therapeutics
Subjects:UNSPECIFIED
Group:Faculty of Science and Technology
ID Code:23284
Deposited By: Unnamed user with email symplectic@symplectic
Deposited On:16 Mar 2016 14:30
Last Modified:26 Apr 2016 14:45

Downloads

Downloads per month over past year

More statistics for this item...
Repository Staff Only -